| |
| |
|
| Insider
Information: |
Starr Kevin P |
| Relationship: |
10% Owner |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
12 |
|
| Direct
Shares |
12,946,933 |
|
|
Indirect Shares
|
23,291,181 |
|
|
| Direct
Value |
$332,169,637 |
|
|
|
Indirect Value
|
$1,212,612,254 |
|
|
| Total
Shares |
36,238,114 |
|
|
| Total
Value |
$1,544,781,890 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 53.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Human Genome Sciences Inc |
HGSI |
Director |
2007-07-10 |
695 |
2007-07-10 |
0 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2015-11-12 |
0 |
2013-03-25 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director, 10% Owner |
2015-02-19 |
184,386 |
2015-02-19 |
0 |
Premium* |
|
|
Larimar Therapeutics Inc |
LRMR |
Director |
2015-09-24 |
370,323 |
2015-09-24 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2021-06-16 |
320,659 |
2019-02-12 |
0 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-06-14 |
3,165,624 |
2016-12-16 |
8,760,904 |
Premium* |
|
|
Editas Medicine, Inc. |
EDIT |
10% Owner |
2016-09-06 |
0 |
2016-09-06 |
3,906,176 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
10% Owner |
2016-12-19 |
0 |
2016-12-19 |
5,453,753 |
Premium* |
|
|
Jounce Therapeutics Inc |
JNCE |
10% Owner |
2017-02-01 |
3,048,780 |
2017-02-01 |
0 |
Premium* |
|
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2017-04-12 |
31,419 |
2017-04-12 |
5,170,348 |
Premium* |
|
|
Allena Pharmaceuticals, Inc. |
ALNA |
10% Owner |
2017-11-06 |
2,790,964 |
2017-11-06 |
0 |
Premium* |
|
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
2018-08-22 |
3,034,083 |
2018-07-23 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
88 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2013-03-25 |
4 |
AS |
$23.56 |
$627,557 |
D/D |
(26,631) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2013-03-26 |
4 |
AS |
$23.41 |
$608,577 |
D/D |
(26,000) |
0 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2014-06-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,791,878) |
0 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • • |
2014-09-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(885,567) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2014-09-24 |
4 |
AS |
$77.48 |
$3,558,557 |
D/D |
(45,000) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2014-09-25 |
4 |
AS |
$76.36 |
$3,469,881 |
D/D |
(45,000) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • • |
2015-01-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(694,931) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • • |
2015-01-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,336,271) |
0 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • • |
2015-02-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,830,285) |
0 |
0 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • • |
2015-03-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,746,658) |
0 |
0 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • • |
2015-05-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,443,935) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • • |
2015-06-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,064,607) |
0 |
0 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • • |
2015-07-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,679,081) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • • |
2015-08-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,480,703) |
0 |
0 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • – |
2015-09-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,131,265) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2015-11-11 |
4 |
AS |
$105.31 |
$4,037,033 |
D/D |
(37,500) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • • |
2015-11-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,809,832) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2015-11-12 |
4 |
AS |
$100.01 |
$3,755,085 |
D/D |
(37,500) |
0 |
0 |
- |
|
| EDIT |
Editas Medicine, Inc. |
10% Owner |
– – • |
2016-09-06 |
4 |
S |
$15.90 |
$93,666 |
D/D |
(5,890) |
0 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
10% Owner |
– – • |
2016-12-19 |
4 |
S |
$28.19 |
$3,002,351 |
D/D |
(106,489) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2019-02-12 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2007-07-10 |
4 |
A |
$8.99 |
$6,250 |
D/D |
695 |
695 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • • |
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,124 |
6,124 |
0 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • • |
2014-06-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,108 |
|
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • – |
2015-01-08 |
4 |
A |
$40.04 |
$49,970 |
D/D |
1,248 |
9,356 |
0 |
- |
|
88 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
